NTRA Insider Trading

Insider Ownership Percentage: 7.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $96,526,554.68

Natera Insider Trading History Chart

This chart shows the insider buying and selling history at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$34MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Natera Share Price & Price History

Current Price: $168.19
Price Change: Price Decrease of -4.42 (-2.56%)
As of 02/20/2025 05:00 PM ET

This chart shows the closing price history over time for NTRA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFeb$172.61Closing price on 02/19/25:

SEC Filings (Institutional Ownership Changes) for Natera (NASDAQ:NTRA)

99.90% of Natera stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NTRA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.55Bbought$13BsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10B-$5B$0$5B$10BTotal InflowsTotal Outflows
Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
Read More on Natera

Today's Range

Now: $168.19
Low: $165.34
High: $173.91

50 Day Range

MA: $168.03
Low: $155.20
High: $177.00

52 Week Range

Now: $168.19
Low: $69.14
High: $183.00

Volume

1,458,287 shs

Average Volume

1,334,766 shs

Market Capitalization

$22.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Who are the company insiders with the largest holdings of Natera?

Natera's top insider investors include:
  1. Roelof Botha (Director)
  2. Matthew Rabinowitz (Chairman)
  3. Jonathan Sheena (Insider)
  4. Steven Leonard Chapman (CEO)
  5. Daniel Rabinowitz (Insider)
  6. John Fesko (Insider)
  7. Solomon Moshkevich (Insider)
  8. Michael Burkes Brophy (CFO)
  9. Herm Rosenman (Director)
  10. James Healy (Director)
  11. Gail Boxer Marcus (Director)
  12. Rowan E Chapman (Director)
Learn More about top insider investors at Natera.

Who are the major institutional investors of Natera?

Natera's top institutional shareholders include:
  1. Vanguard Group Inc. — 9.33%
  2. Price T Rowe Associates Inc. MD — 5.11%
  3. JPMorgan Chase & Co. — 5.08%
  4. Farallon Capital Management LLC — 3.36%
  5. Wellington Management Group LLP — 2.45%
  6. Fred Alger Management LLC — 2.29%
Learn More about top institutional investors of Natera stock.

Which institutional investors are selling Natera stock?

In the previous quarter, NTRA stock was sold by these institutional investors:
  1. Capstone Investment Advisors LLC
  2. Calamos Advisors LLC
  3. D. E. Shaw & Co. Inc.
  4. Lord Abbett & CO. LLC
  5. Alberta Investment Management Corp
  6. Voya Investment Management LLC
  7. FMR LLC
  8. Invesco Ltd.
Within the last year, company insiders that have sold Natera company stock include:
  1. Roelof Botha (Director)
  2. Matthew Rabinowitz (Chairman)
  3. Jonathan Sheena (Insider)
  4. Steven Leonard Chapman (CEO)
  5. Daniel Rabinowitz (Insider)
  6. John Fesko (Insider)
  7. Solomon Moshkevich (Insider)
  8. Michael Burkes Brophy (CFO)
  9. Herm Rosenman (Director)
  10. James Healy (Director)
Learn More investors selling Natera stock.

Which institutional investors are buying Natera stock?

In the last quarter, NTRA stock was purchased by institutional investors including:
  1. Price T Rowe Associates Inc. MD
  2. JPMorgan Chase & Co.
  3. Norges Bank
  4. Raymond James Financial Inc.
  5. Vanguard Group Inc.
  6. Summit Partners Public Asset Management LLC
  7. Wellington Management Group LLP
  8. Franklin Resources Inc.